Drug Type Monoclonal antibody |
Synonyms NBL 020, NBL-020, NBL020 |
Target |
Action modulators |
Mechanism TNFR2 modulators(Tumor necrosis factor receptor superfamily member 1B modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cutaneous T-Cell Lymphoma | Phase 1 | China | 15 Aug 2023 | |
| Liver metastases | Phase 1 | China | 15 Aug 2023 | |
| Advanced cancer | Phase 1 | China | 14 Aug 2023 | |
| Solid tumor | Phase 1 | United States | 23 Dec 2022 | |
| Hematologic Neoplasms | Phase 1 | China | - | |
| Breast Cancer | IND Approval | China | 13 Feb 2023 | |
| Colonic Cancer | IND Approval | China | 13 Feb 2023 | |
| Lung Cancer | IND Approval | China | 13 Feb 2023 | |
| Ovarian Cancer | IND Approval | China | 13 Feb 2023 |






